Sartorius simplifies biologics production with new bioreactor

BIOSTAT STR Generation 3, 2000 L.
Company launches BIOSTAT STR Generation 3 bioreactor with BIOBRAIN automation platform.
Engineered to address the rigorous requirements and complexity of biologics manufacture, Sartorius now offers its BIOSTAT STR Generation 3 single-use bioreactor and BIOBRAIN automation platform to change biopharmaceutical process development and manufacturing.
BIOSTAT STR is a robust industrial platform consisting of hardware, software and consumables for single-use process development and commercial biomanufacturing. This generation of bioreactors and Flexsafe STR bags range from 12.5 L to 2000 L in working volume.
The system is powered by BIOBRAIN, a new automation platform that gives biologics manufacturers the flexibility to quickly and easily configure the BIOSTAT STR system to meet their precise needs. Data-driven software, a comprehensive suite of analytical tools and experienced engineering design and support teams enable manufacturers to produce consistent results, even in the setting of changing demands.
Fully integrated and redundant single-use sensors provide real-time data to measure and control key critical process parameters such as pH, DO, viable biomass, glucose, lactate and foam. Non-invasive measurements save set-up time, prevent interface issues and reduce the need for off-line manual sampling. These monitoring and control systems enhance batch-to-batch consistency and operator confidence.
BIOSTAT STR Generation 3 is ready for process intensification and includes functionalities such as feed controls, bleed controls and connectivity to Repligen’s XCell ATF cell retention devices to increase cell density and productivity.
Connection to Umetrics SIMCA enables predictive, multivariate modeling and control, allowing manufacturers to predict yield and optimal harvest time points at the early stages of the perfusion process.
Integration into existing process infrastructure can be achieved in multiple ways: local management via the BIOSTAT STR control tower and BIOBRAIN automation platform with connection to data histories, or full process management via distributed control systems from Emerson, Siemens or Rockwell. An additional feature for BIOSTAT STR Generation 3 is the optional integration of native Emerson DeltaV controls supported by a Sartorius DeltaV library, which affords full access and control from DeltaV systems.
Sartorius engineering and technical field experts help design and implement new facilities and retrofits, address scaling challenges and manage technology transfers. This level of support relieves internal development and manufacturing teams from the burden of developing master status on new technology.

Related News
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Trump administration halts global supply of HIV, malaria, tuberculosis drugs
In various memos circulated to the United States Agency for International Development (USAID), the Trump administration has demanded contractors and partners to immediately stop work in supplying lifesaving drugs for HIV, malaria, and tuberculosis to c... -
News 2024 Drug Approvals: a lexicon of notable drugs and clinical trials
50 drugs received FDA approval in 2024. The centre for biologics evaluation and research also identified six new Orphan drug approvals as under Biologics License Applications (BLAs). The following list picks out key approvals from the list, and highlig...
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance